Ultragenyx Pharma (RARE) Misses Q4 EPS by 5c; offers guidance

Ultragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.39), $0.05 worse than the analyst estimate of ($1.34). Revenue for the quarter came in at $164.88 million versus the consensus estimate of $146.59 million.

GUIDANCE:

Ultragenyx Pharma sees FY2025 revenue of $640-670 million, versus the consensus of $651.9 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• Oppenheimer Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
• Lonza Group (LONN:SW) (LZAGY) PT Raised to CHF720 at RBC Capital